2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Clinical Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Devices, Surgical, Women’s Health, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, VWD, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4803 The epidemiology and clinical burden of hemophilia in low- and middle-income countries: A scoping review

Kelly Pimenta, PhD, MPH, Nidhi Bhatt, MD2, Isabella Pennington3, Catherine Barclay4, Pramika Sriram5, Kayla Henry6, Jane Hankins, MD,MS7, Lisa Force, MD, MPH8, Ulrike Reiss, MD9
1 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
4 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
5 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
6 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
7 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
8 University of Washington, Seattle, Washington, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Background: Hemophilia A and B are inherited X-linked recessive bleeding disorders caused by deficiency of coagulation factor VIII or IX, resulting in lifelong bleeding complications that can lead to chronic arthropathy, disability, and premature mortality without timely diagnosis and effective treatment. Advances in hemophilia diagnosis and treatment have substantially improved survival and quality of life in high-income countries. However, nearly 70% of people with hemophilia are estimated to live in low- and middle-income countries (LMIC), where fewer than 12% are identified. Delayed diagnosis, restricted access to comprehensive care and coagulation factor replacement therapy, and fragmented surveillance contribute to inconsistent reporting and incomplete characterization of hemophilia in LMIC. Although global estimates are available, evidence from LMIC remains fragmented and heterogeneous. A comprehensive synthesis is needed to characterize the available evidence, identify gaps, and inform research and policy priorities.

Objective: To summarize the quantity and quality of data reporting the epidemiology and clinical burden of hemophilia A and B in LMIC.

Methods: We conducted a scoping review following PRISMA-ScR reporting guidelines. PubMed/MEDLINE, Embase, Scopus, Web of Science, Global Health, and additional databases were searched for studies published between 1980 and 2025. Observational studies of any geographic scope (national, regional, registry-based, hospital-based, clinic-based) that reported original epidemiologic or clinical data among individuals with hemophilia in LMIC were included. Studies with ineligible populations, outcomes, or designs were excluded. Countries were classified as LMIC using the 2025 World Bank income classification. Outcomes included prevalence, incidence, mortality, join bleeding and arthropathy, intracranial and intra-abdominal hemorrhage, HIV and Hepatitis B/C infection, factor VIII and IX inhibitor, and perinatal, postnatal, peripartum, and postpartum bleeding. Two reviewers independently screened titles, abstracts, and full-text articles using extracted data applying Covidence software, and assessed study quality. Discrepancies were resolved by a third reviewer.

Results: The search identified 11,126 records; 9,221 remained after duplicate removal. Of 323 full-text articles assessed, 123 met inclusion criteria. The median publication year was 2016. The literature represented a broad geographic distribution across LMIC, with studies most frequently conducted in India (15 studies, 12.2%), Brazil (13 studies, 10.6%), Iran (12 studies, 9.8%), China (11 studies, 8.9%), Turkey (7 studies, 5.7%), and Pakistan (6 studies, 4.9%), along with additional reports from Africa, and other Middle Eastern, Asian, and Latin American countries. Collectively, these six countries accounted for 52% (64/123) of all included studies despite representing only 8% of all 71 target LMIC, underscoring the geographic concentration of the evidence base.

 The published literature was primarily weighted toward diagnosis and genetic characterization (83/123, 67.5%), prevalence and incidence (71/123, 57.7%), and treatment patterns and access to care (68/123, 55.3%). Clinical complications were also commonly evaluated, including inhibitor development (48 studies, 39.0%), transfusion-transmitted infections, such as HIV and hepatitis B/C (47 studies, 38.2%), intracranial hemorrhage (45 studies, 36.6%), and joint bleeding or hemophilic arthropathy (30 studies, 24.4%). Evidence on longer-term and patient-centered outcomes remained sparse: only 18 studies (14.6%) reported mortality or survival, 7 (5.7%) reported quality of life or disability, and 8 (6.5%) reported outcomes among women and carriers, distinct from the acute-complication counts above, few studies tracked these as dedicated longitudinal outcomes.

Conclusion: This comprehensive review of published evidence on the burden of hemophilia in LMIC identifies that data is concentrated in a small subset of LMIC and weighted toward diagnosis and genetics, prevalence and incidence, and treatment access. However, less frequently evaluated are mortality, disability, quality of life – critical measures used in health policy development and health economics for planning and improving care and treatment access.

Kelly Pimenta, PhD, MPH: American Lebanese Syrian Associated Charities (ALSAC) - Research Funding